Loading clinical trials...
Loading clinical trials...
A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults With Refractory Solid Tumors
Conditions
Interventions
Recombinant human interleukin-15 (rhIL-15)
NK Cell Infusion
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
June 11, 2013
Primary Completion Date
September 8, 2015
Completion Date
September 8, 2015
Last Updated
April 24, 2026
NCT07489378
NCT07548177
NCT07181681
NCT07467772
NCT07360314
NCT07204340
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions